Interim analysis findings showed the perioperative treatment group demonstrated a statistically significant improvement in event-free survival compared with adjuvant radiotherapy, with or without ...

FDA grants breakthrough status to Rybrevant Faspro for recurrent or metastatic HPV-negative head and neck cancer after prior therapy.

Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...

Neoadjuvant immunotherapy in combination with chemotherapy in resectable locally advanced head and neck squamous cell carcinoma: A randomized, open label, phase II clinical trial. This is an ASCO ...

Panelists discuss how recurrent metastatic head and neck squamous cell carcinoma (HNSCC) manifests through symptoms such as persistent sore throat and neck lumps, with risk factors including tobacco ...

Functional Impact of Transoral Surgery and Risk-Based Adjuvant Therapy in Human Papillomavirus–Associated Oropharyngeal Cancer: Swallowing Outcomes From ECOG-ACRIN E3311 Impaired homologous ...

Schematic representation depicts the mechanism by which the ENO2-derived oncometabolite PEP directly binds to HDAC1 and thereby promotes H3K18la, which promotes macrophage polarization and leads to ...